AKTS

Rating neutralAI Memo

Aktis Oncology

As of 2026-07-14/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-14 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

AKY-2519 Phase 1b expansion in 2H 2026 • 2026-12-31

Expected move: +17%

Biggest risk

The company remains a low-coverage, clinical-stage biotech with valuation dependent on trial execution and future data. The Q1 per-share loss miss, possible development delays, weak peer comparability, and clinical or financing risk could pressure the shares.

Invalidation

Break below $17 or thesis failure.

What would change my mind?

Aktis is advancing two clinical-stage radiopharmaceutical programs, with AKY-2519 now in Phase 1b and AKY-1189 enrolling across multiple Nectin-4-expressing tumor types. Successful trial execution and credible 2027 preliminary data could support substantial re-rating.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-14

Base target

$29

p=50%

Bull target

$40

p=25%

Bear target

$17

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 earnings digestion remains a near-term overhang
Preliminary data from both lead programs in 2027
Aktis is advancing two clinical-stage radiopharmaceutical programs, with AKY-2519 now in Phase 1b and AKY-1189 enrolling across multiple Nectin-4-expressing tumor types.

BearKey bullets

Clinical data may fail to demonstrate sufficient efficacy, safety, dosimetry, or target engagement.
Delays in enrolling or expanding AKY-1189 and AKY-2519 trials could defer the main valuation catalysts.
Peer comparisons are loose and do not provide a dependable valuation benchmark.

WatchKey bullets

AKY-2519 Phase 1b expansion in 2H 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $29 (p=50%)

Bull/Bear spread: +61% / -32%

Vs latest close: Bull +61% · Base +17% · Bear -32%

Scenario probabilities

Bull Target: $40 (p=25%)Base Target: $29 (p=50%)Bear Target: $17 (p=25%)

Commentary

Sentiment is mixed-to-cautious: company disclosures show meaningful clinical progress, while earnings coverage highlighted an EPS miss. Social context, insider activity, and post-print analyst revisions are unavailable, so there is no independent confirmation of a stronger near-term trend.

As of 2026-07-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 earnings digestion remains a near-term overhang
Preliminary data from both lead programs in 2027

Scenarios

Bull Target (Scenario probability)

$40 / p=25% prob

Base Target (Scenario probability)

$29 / p=50% prob

Bear Target (Scenario probability)

$17 / p=25% prob

Price $25 as of 2026-07-17

Nearest Scenario: Base (∆ 17%)

Targets vs latest close: Bull +61% · Base +17% · Bear -32%

Sentiment & Exposure

News Sentiment (30d)

-0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
AKY-2519 Phase 1b expansion in 2H 2026
Aktis has initiated the mCRPC Phase 1b trial and plans a second basket trial in additional solid tumors during the second half of 2026. Execution against this schedule is the key intermediate de-risking test. [#SEC-8K-2026-05-11]
Prob 60.00% • Move 12.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Q1 earnings digestion remains a near-term overhang
2026-07-31
Associated Press coverage reported a $0.38 quarterly loss versus a $0.31 analyst estimate, although revenue exceeded expectations. With limited coverage, near-term sentiment may remain cautious until clinical execution reasserts itself. [#PR-EARNINGS-2026-05-12]
Prob 70% • Move -6% • Priced-in 65%

Long-term Catalysts

Months to a year

Preliminary data from both lead programs in 2027
2027-03-31
Management expects preliminary AKY-2519 data in 2027 and preliminary AKY-1189 Phase 1b data in the first quarter of 2027. These readouts are the principal longer-term value inflection points, but remain clinically uncertain. [#SEC-8K-2026-05-11] [#SEC-8K-2026-03-30]
Prob 55% • Move 25% • Priced-in 30%

Risks

Clinical data may fail to demonstrate sufficient efficacy, safety, dosimetry, or target engagement.
Delays in enrolling or expanding AKY-1189 and AKY-2519 trials could defer the main valuation catalysts.
Peer comparisons are loose and do not provide a dependable valuation benchmark.
The Q1 loss miss and limited analyst coverage increase sensitivity to financing, execution, and sentiment shocks.
The company is pre-commercial and may require additional capital before pivotal development or commercialization.

Peers

Symbol	Summary
BLFS	Similar market capitalization and sector classification, but the packet does not establish modality or indication overlap; useful for small-cap life-science risk context rather than operating read-through.
NNNN	Similar sector and market-cap screen candidate, but no evidence in the packet supports a direct radiopharmaceutical comparison; peer relevance is weak.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-14

AI Stock Memo: AKTS - Aktis Oncology - RankAlpha